Oruka Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oruka Therapeutics, Inc. (Nasdaq: ORKA) on September 22, 2025, reporting events occurring on September 17, 2025. The filing details a private placement of equity securities and the announcement of clinical data for the company's lead asset, ORKA-001.
Key Financial Metrics and Capital Structure
- Capital Raised: Approximately $180 million in aggregate purchase price.
- Securities Issued:
- 10,933,405 shares of Common Stock at $15.00 per share.
- 1,066,666 Pre-Funded Warrants at $14.999 per warrant (exercisable for Common Stock at $0.001).
- Share Count (Post-Closing): 48,384,150 shares of Common Stock issued and outstanding as of September 19, 2025.
- Pro Forma Share Count: Approximately 67.1 million shares, assuming full conversion of Series B Non-Voting Convertible Preferred Stock and exercise of all outstanding pre-funded warrants.
- Placement Agents: Jefferies LLC, TD Securities (USA) LLC, Guggenheim Securities, LLC, and LifeSci Capital LLC.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement and a Registration Rights Agreement with institutional and accredited investors. The private placement closed on September 19, 2025. Under the Registration Rights Agreement, the Company must file a registration statement for the resale of the securities by October 15, 2025, and use commercially reasonable efforts to have it declared effective within 90 days. The securities were sold in reliance on Section 4(a)(2) of the Securities Act of 1933.
Outlook, Management Commentary, and Risks
On September 17, 2025, the Company announced clinical data from its Phase 1 trial of ORKA-001 and upcoming scientific presentations at the European Academy of Dermatology and Venereology Congress. The filing notes that the information regarding the clinical data is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act. The filing does not provide specific revenue, profit, cash flow, or debt metrics, as this is a current report focused on a specific transaction rather than a periodic financial statement.
Investor Verification Checklist
- Verify the exact terms of the Pre-Funded Warrants, including the 9.99% beneficial ownership limitation and the 61-day notice requirement to increase this threshold to 19.99%.
- Confirm the timeline for the registration statement filing (due October 15, 2025) and its effectiveness.
- Review the full text of the press releases (Exhibits 99.1 and 99.2) for specific details on the Phase 1 clinical data for ORKA-001, as the 8-K only references their existence.
- Assess the dilution impact of the pro forma share count (67.1 million) versus the current outstanding count (48.4 million).
- Check for any subsequent filings regarding the conversion of Series B Non-Voting Convertible Preferred Stock.